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Abstract Selective protein kinase C (PKC) activators and
inhibitors were used to investigate the involvement of specific
PKC isoforms in the modulation of voltage-sensitive Ca2+
channels (VSCCs) in bovine adrenal chromaffin cells. Exposure
to the phorbol ester phorbol-12,13-dibutyrate (PDBu) inhibited
the Ca2+ currents elicited by depolarizing voltage steps. This
inhibition was occluded by the PKC-specific inhibitor Ro 31-
8220 but remained unaffected by Go« 6976, a selective inhibitor of
conventional PKC isoforms. PDBu treatment caused the
translocation of PKC-K and -O isoforms from cytosol to
membranes. PKC-S and -j showed no signs of translocation. It
is concluded that VSCCs are specifically inhibited by the
activation of PKC-O in chromaffin cells. This may be relevant
to the action of phospholipase-linked receptors involved in the
control of Ca2+ influx, both in catecholaminergic cells and other
cell types. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
The protein kinase C (PKC) superfamily comprises at least
12 isoforms: the conventional (cPKC) isoforms (Ca2- and
diacylglycerol/phorbol ester-sensitive forms K, LI, LII and Q),
the novel (nPKC) isoforms (Ca2-insensitive and diacylglycer-
ol/phorbol ester-sensitive forms O, R, N and a), the atypical
(aPKC) isoforms (Ca2- and diacylglycerol/phorbol ester-in-
sensitive forms j and V/S) and the recently discovered PKC-
related kinases [1]. The PKC isoforms di¡er in their structure,
cofactor requirements, substrate speci¢city and tissue expres-
sion with speci¢c subcellular distribution [2]. These features,
combined with the ¢nding that more than one PKC isoform is
usually expressed in a single cell type, have led to the notion
that each member of the PKC superfamily plays a speci¢c role
in the processing of physiological and pathological responses
to extracellular stimuli.
Voltage-sensitive Ca2 channels (VSCCs) are prone to mod-
ulation by PKC. Indeed, PKC activation has been shown to
either enhance or inhibit depolarization-evoked Ca2 currents
(ICa) depending on the cell type. Speci¢cally, we and others
have previously demonstrated that the PKC activator phorbol
12-myristate 13-acetate (PMA) inhibits depolarization-evoked
Ca2 in£ux in catecholamine-secreting adrenal chroma⁄n
cells [3^5], and that L-type VSCCs appear to be the major
target for this inhibition [6]. Using a combination of patch-
clamp and PKC translocation studies, we have now deter-
mined the PKC isoform speci¢city of phorbol ester-mediated
inhibition of voltage-activated calcium currents in chroma⁄n
cells.
2. Materials and methods
Bovine adrenal medulla cells were isolated, puri¢ed and cultured
essentially as described [6,7]. Experiments were performed between
days 2 and 5 of culture.
The whole-cell patch-clamp technique was used to record ICa, es-
sentially as reported [8]. Patch pipets were ¢lled with a solution con-
taining (in mM): 110 CsCl, 20 TEACl, 14 EGTA (ethylene glycol
bis(L-aminoethyl ether)-N,N,NP,NP-tetraacetic acid), 5 MgATP, 0.2
Na2GTP and 20 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
(HEPES; pH 7.2, adjusted with CsOH). Currents were recorded using
an Axopatch 200A voltage-clamp ampli¢er and pCLAMP software
(version 5.5; Axon Instruments, Foster City, CA, USA). Data were
acquired at 10^20 kHz and ¢ltered at 5 kHz with an 8-pole low-pass
Bessel ¢lter. Cells were superfused with di¡erent salt solutions (£ow
rate6 1.5 ml min31) using a £ow system in which seven lines fed a
common out£ow placed near the cell [9]. The perfusion salt solution
used at the start of each experiment contained (in mM): 125 NaCl, 5.4
KCl, 1 MgCl2, 5 CaCl2, 10 glucose and 10 HEPES (pH 7.4, adjusted
with NaOH). This solution was subsequently replaced by a Na-free
solution containing (in mM): 125 choline chloride, 5 CaCl2, 1 MgCl2,
5.4 CsCl2, 10 glucose and 10 HEPES (pH 7.4, adjusted with
TEAOH). All the experiments were conducted at room temperature
(20^23‡C).
For PKC immunodetection, cultured chroma⁄n cells were washed
with Earle’s balanced salt solution and maintained in culture for a
further 24 h period in heat-inactivated fetal calf serum-free Dulbecco’s
modi¢ed Eagle’s/Ham’s F-12 medium. The cells were then treated
with phorbol-12,13-dibutyrate (PDBu) for the various time periods
indicated in Fig. 1. For the assessment of the amounts of soluble
and membrane-associated PKC isoforms, cells were subsequently
washed, harvested and lysed as described previously [7]. The protein
samples were subjected to sodium dodecyl sulfate^polyacrylamide gel
electrophoresis and transferred to nitrocellulose membranes as de-
scribed [7]. For immunoblotting, monoclonal antibodies raised against
the di¡erent PKC isoforms (K, L, Q, N, O, j, a, R, S, V and W) were used
and immunoreactive proteins detected using an enhanced chemilumi-
nescence detection system. Immunoblotting and densitometric analysis
were performed as described previously [7].
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For PKC activity determination, cultured chroma⁄n cells were
washed, harvested and scraped into ice-cold homogenization bu¡er
as described previously [7]. The cells were lysed in a Te£on pestle
tissue grinder and centrifuged for 10 min at 14 000Ug to remove
insoluble cellular components (4‡C). PKC activity was assessed by a
£uorescence assay (Colorimetric PKC Assay Kit, SpinZyme Format;
Pierce, Rockford, IL, USA), based on a⁄nity separation of the phos-
phorylated form of a protein substrate (pseudosubstrate peptide), co-
valently attached to a £uorescent label. The reaction bu¡er contained
excess Ca2 and phosphatidyl-L-serine, thus allowing for detection of
both conventional and novel PKC isoforms.
Values are expressed as mean þ S.E.M. throughout the text and
¢gures. The statistical signi¢cance of di¡erences between mean values
was assessed by either one-way analysis of variance (ANOVA) fol-
lowed by Bonferroni’s multiple comparisons test or paired Student’s
t-test, as appropriate.
Go« 6976 and PMA were from Calbiochem (Nottingham, UK). R0
31-8220 was a kind gift of Dr. G. Lawton (Roche Products Ltd,
Welwyn, Herts, UK). PDBu and all other reagents were from either
Sigma (St. Louis, MO, USA) or Merck (Darmstadt, Germany). Re-
agents for the immunodetection of PKC were as previously described
[10] with the exception of monoclonal antibodies against PKC iso-
forms (Transduction Laboratories, Exeter, UK).
3. Results
We [7] and others [10] have previously reported the presence
of PKC-K, -O and -j isoforms in bovine chroma⁄n cells. In
the present study we have tested additional PKC antisera and
found evidence for another aPKC isoform, PKC-S. The di¡er-
ential translocation of PKC isoforms from cytosol to mem-
branes in response to treatment with phorbol esters has been
widely reported. To understand the e¡ects of several minutes
exposure to PDBu (1 WM) on the detectable isoforms of PKC
in chroma⁄n cells, we investigated its distribution between
the cytosolic and membrane fractions using cells cultured in
serum-free conditions for 24 h.
Fig. 1 shows that both PKC-K and -O translocated rapidly
from cytosol to membranes. Indeed, PKC-K and -O immuno-
reactivities in the membrane pool reached maximal levels at
10 min of PDBu treatment (not di¡erent to membrane PKC-K
and -O immunoreactivities at 90 min; Ps 0.05, assessed by
ANOVA). It is also noteworthy that the loss of PKC-O
from the cytosol at 10 min of PDBu treatment (V66%) was
more profound than the loss of PKC-K (V42%). However,
Fig. 1D suggests that the amount of membrane-bound PKC-K
at this time point exceeds largely that of membrane-bound
PKC-O. This is presumably a consequence of cytosolic PKC-
K being present in larger amounts relative to cytosolic PKC-O.
PKC-S and -j showed no signi¢cant signs of translocation.
Maximal translocation of PKC-O and -K from cytosol to
membranes occurred at approximately 100 nM PDBu
(EC50 = 8 and 17 nM, respectively; data not shown). We
therefore set at 200 nM the PDBu concentration to be used
in the electrophysiological experiments.
Whole-cell ICa in chroma⁄n cells were recorded using Ca2
(5 mM) in the extracellular solution as the charge carrier. Fig.
2A depicts the typical appearance of ICa recorded under con-
trol conditions and in the continued presence (10 min) of
PDBu (200 nM). Control ICa reached a peak (3375 þ 29 pA,
þ S.E.M.; n = 12 cells) in less than 8 ms and was partially
inactivated thereafter.
Fig. 1. Translocation of PKC isoforms from cytosol to membranes in response to PDBu. A, B: E¡ect of exposure to 1 WM PDBu for between
10 and 180 min on levels of PKC-K, -O, -j and -S immunoreactivity on Western blots of cytosolic (A) and membrane (B) fractions from chro-
ma⁄n cells (autoradiographs of typical experiments). C, D: Pooled immunoreactivity data, collected by laser densitometry of autoradiographs
from six di¡erent experiments for cytosolic (C) and membrane (D) fractions. Cytosolic readings were normalized to the untreated control levels
expressed as 100%. Membrane-bound readings were normalized to fold over unstimulated controls. Data are mean þ S.E.M. values.
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Following stabilization of the ICa, identical voltage steps
were applied to each cell every 30 s. Fig. 2B shows that
peak ICa remained fairly constant for several minutes prior
to addition of PDBu. The phorbol ester caused a pronounced,
time-dependent reduction in peak ICa amplitude that appeared
to stabilize in less than 10 min (representative trace in Fig.
2A). On average, the inhibition of peak ICa at this time point
amounted to 29 þ 3% of control (average peak ICa recorded
6 min prior to PDBu addition). The time necessary to cause
50% of maximal inhibition (t1=2) was 4.1 þ 0.5 min (n = 12
cells). The time course of the PDBu-mediated inhibition of
ICa is therefore similar to that reported in a previous study
from our laboratory, using PMA as a pharmacological tool to
activate PKC and [Ca2]i measurements from single cells as
an indirect way of assessing depolarization-evoked ICa [5].
PDBu did not appear to a¡ect the inactivation properties of
ICa, as shown in Fig. 2A.
The typical e¡ect of another phorbol ester activator of PKC
(PMA, 200 nM) on ICa is depicted in Fig. 2C. PMA reduced
peak ICa (average inhibition at 10 min incubations: 43 þ 4% of
control, n = 12 cells) with a time course similar to that of
PDBu (average t1=2 : 5.0 þ 0.3 min). ICa seemed to undergo
faster inactivation in the presence of PMA. We have deter-
mined whether the phorbol ester-mediated reduction in peak
ICa might originate from a rightward shift in the voltage de-
pendency of Ca2 channel activity. The I^V curve depicted in
Fig. 2D shows that control ICa did not develop prior to step-
ping membrane potential to ca. 320 mV, reached a maximum
at ca. 0 mV and reversed at around +50 mV (average reversal
potential : +46.7 þ 0.6 mV, n = 5 cells). PMA depressed peak
ICa at all voltages in the range 310/+40 mV but did not alter
its activation mid-point, as determined by ¢tting the I^V curve
data to a modi¢ed Boltzmann function: 39.1 þ 0.5 mV versus
39.5 þ 0.6 mV (n = 5 cells) for control and PMA, respectively.
This is in keeping with data from other studies [11].
We have determined whether PKC activation mediates the
inhibitory e¡ect of PDBu by pre-incubating the cells with the
speci¢c PKC inhibitor Ro 31-8220 [12]. This compound ad-
mittedly inhibits most, if not all PKC isoforms known to date.
Fig. 3A shows that addition of Ro 31-8220 (10 WM) caused a
signi¢cant reduction in peak ICa. On average this inhibition
amounted to 23 þ 4% (Fig. 3B). Peak ICa values were none-
theless fully recovered following inhibitor washout and, sig-
ni¢cantly, exposing Ro 31-8220-pretreated cells to 200 nM
PDBu occluded the phorbol ester-mediated inhibition of
peak ICa (inset to Fig. 3A, compare traces a and c). There
Fig. 2. Inhibitory e¡ects of PKC activators on voltage-activated ICa. A: Superimposed current traces obtained in the absence (‘control’) and
presence of the phorbol ester PDBu (200 nM, 10 min). Whole-cell ICa were elicited by stepping membrane potential to 0 mV from a holding
potential of 380 mV. B: Time course of the average inhibitory e¡ect of 200 nM PDBu on peak ICa. Each cell was repetitively stimulated with
125 ms voltage steps every 30 s as in A. PDBu was added to and removed from the perfusion solution as denoted by the arrows. Data are ex-
pressed as percentage of peak ICa recorded in control (6 min prior to PDBu addition). C: Superimposed sample traces obtained in the absence
(‘control’) and presence of the phorbol ester PMA (200 nM, 10 min). Pulse protocol as in A. D: Current^voltage (I^V) curves obtained under
control conditions (squares) and throughout PMA exposure after 10 min (circles). I^V curves were constructed by applying 260 ms pulses to
various test potentials from a holding potential of 380 mV at 25 s intervals. Data are presented as mean þ S.E.M. (B: n = 12 cells; D: n = 5
cells).
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was in some cells a slight but continued ICa run-down through-
out the experiment (see Fig. 2B, left). This may explain why,
on average, exposing Ro 31-8220-pretreated cells to PDBu
resulted in an apparent 8% inhibition of peak ICa (Fig. 3B).
In the following experiments we used Go« 6976, a speci¢c
inhibitor of cPKC isoforms [13,14]. Go« 6976 concentrations in
the WM range have been shown not to a¡ect nPKC activity in
vitro [13], and have been used to di¡erentiate between cPKC
and non-cPKC e¡ects in di¡erent cell types, including chro-
ma⁄n cells [15^17]. Pretreatment with 10 WM Go« 6976 did
not impair the PDBu-mediated reduction in peak ICa, as
shown in Fig. 3C (compare traces b and c). Indeed, the aver-
age inhibitory e¡ect observed in Go« 6976-pretreated cells
amounted to 48 þ 8% of control (Fig. 3D). This cannot be
accounted for by a reversible action of Go« 6976 on PKC
activity since the inhibitory e¡ect of PDBu remained in the
continued presence of the drug (n = 2 cells, data not shown;
see also [14]). Interestingly, Go« 6976 alone reduced peak ICa
by a modest 9 þ 3% of control (Fig. 3D) when compared with
Ro 31-8220.
We have assessed the e¡ectiveness of Go« 6976 as an inhib-
itor of phorbol ester-induced PKC activity in chroma⁄n cells,
using an incubation protocol similar to that used for the elec-
trophysiological experiments (exposure to 10 WM Go« 6976 for
3 min, followed by phorbol ester addition in the absence of
the PKC inhibitor). Exposing control cells to 200 nM PMA
for 5 min evoked a 2.2-fold increase in PKC activity. This
e¡ect was strongly attenuated (V90%) by pretreating the cells
with 10 WM Go« 6976 (Fig. 3E).
4. Discussion
We have shown that, in adrenal chroma⁄n cells, phorbol
ester activators of PKC lead to the inhibition of VSCCs in a
seemingly voltage-independent manner. This resembles the in-
hibitions observed in other cell types [18]. Importantly, our
data indicate that PKC-mediated inhibition of VSCCs is iso-
form-speci¢c in chroma⁄n cells. Indeed, PDBu inhibition of
voltage-activated ICa is occluded by pretreating the cells with
the membrane-permeant bisindolylmaleimide derivative Ro
Fig. 3. Di¡erential e¡ects of PKC inhibitors on phorbol ester-induced inhibition of voltage-activated ICa. A: E¡ect of PDBu (200 nM) on peak
ICa in a Ro 31-8220-pretreated cell. The cell was repetitively stimulated with 125 ms voltage steps to 0 mV (holding potential 380 mV).
Ro 31-8220 (10 WM) was added to and removed from the perfusion solution as denoted by the arrows. PDBu was applied as indicated by the
horizontal bar. Inset: Superimposed current traces obtained in the absence (a) and presence of Ro 31-8220 (b), and after exposure to PDBu
(c). B: Average inhibitory e¡ects of Ro 31-8220 alone (left column) and PDBu (200 nM, 10 min) in Ro 31-8220-pretreated cells. Data are ex-
pressed as percentage of peak ICa recorded in control (2 min prior to Ro 31-8220 pretreatment). Data from the experiment depicted in A and
six similar experiments. C: Same as in A, except that the PKC inhibitor was Go« 6976 (10 WM). D: Average inhibitory e¡ects of Go« 6976 alone
(left column) and PDBu (200 nM, 10 min) in Go« 6976-pretreated cells. Data are expressed as in B. Data from the experiment depicted in C
and three similar experiments. E: E¡ect of Go« 6976 pretreatment on PKC activity. Cells were stimulated with 200 nM PMA for 5 min both in
the absence of Go« 6976 (left column) and after Go« 6976 pretreatment (10 WM, 3 min). Data are expressed as percentage of PKC activity mea-
sured in control (5 min exposures to 0.01% dimethylsulfoxide). Absolute PKC activity in control: 4.7 þ 1.0 mU. PKC activity data were ob-
tained from four experiments in triplicate. Data are presented as mean þ S.E.M. (B, D and E).
FEBS 24690 5-3-01
C.M. Sena et al./FEBS Letters 492 (2001) 146^150 149
31-8220. This compound shows little PKC isoform selectivity
and inhibits all PKC isoforms tested, including the isoforms
expressed in chroma⁄n cells [12]. In contrast, the PDBu in-
hibition of ICa is una¡ected by pretreating the cells with the
indolocarbazole Go« 6976. This compound discriminates be-
tween Ca2- and non-Ca2-dependent isoforms of PKC in
vitro, inhibiting the cPKC isoforms (including PKC-K), but
not the nPKC and aPKC isoforms (including PKC-O)
[13,15,19]. Lack of e¡ect of Go« 6976 in the present study
cannot be explained by ready washout from the cell mem-
branes at the time of exposure to PDBu, since pretreating
the cells with Go« 6976 caused a profound inhibition of phor-
bol ester-induced PKC activity. The di¡erential action of Ro
31-8220 and Go« 6976, reported in this study, points to PKC-O
speci¢cally mediating PDBu inhibition of ICa, since it is the
only nPKC isoform present in chroma⁄n cells (this work and
[7,10,17]). It should be emphasized, in this respect, that PKC-O
undergoes ready translocation from cytosol to membranes,
and that the time course of this translocation (maximal e¡ect
reached in 10 min or less of PDBu treatment) is compatible
with the kinetics of the inhibitory e¡ect of PDBu on ICa
(t1=2V4 min, maximal inhibition in less than 10 min). This
is an important point, since PKC translocation is generally
regarded as representing the primary mode of activation of
the kinase in mammalian cells [20,21].
One possibility to account for the fact that VSCCs in chro-
ma⁄n cells are prone to regulation by speci¢c PKC isozymes
is that activated PKC might be targeted to discrete sites in the
plasma membrane in an isoform-speci¢c fashion [20,22]. Ac-
cording to this model, activated PKC-O in chroma⁄n cells
would be targeted to discrete sites in the close vicinity of
VSCCs (most likely of the L-type [6]). In addition, we hy-
pothesize that activated PKC-K might be targeted to mem-
brane sites unrelated to Ca2 in£ux, thereby meeting alterna-
tive regulatory requirements in chroma⁄n cells. We note in
this respect that bradykinin and histamine receptor responses
are di¡erentially regulated by PKC isoforms in chroma⁄n
cells [7], suggesting again that PKC-K and -O might be specif-
ically targeted to discrete sites in the plasma membrane in
close vicinity to these receptors (or associated G-protein/phos-
pholipase C molecules). Also interestingly, PKC-K and -O ap-
pear to be di¡erentially involved in the down-regulation of
voltage-sensitive Na channels in chroma⁄n cells [17]. Other
possibilities can nonetheless be invoked to account for the
selective regulation of VSCCs by PKC-O in chroma⁄n cells.
For example, cPKC and nPKC isoforms may display some
degree of selectivity towards the Ca2 channel phosphoryla-
tion sites. To our knowledge, this hypothesis has not yet been
addressed conclusively.
The physiological signi¢cance of the isoform-speci¢c regu-
lation of VSCCs by PKC-mediated phosphorylation remains
unknown. It is however a likely possibility that selected phos-
pholipase-linked receptors might regulate Ca2 in£ux in a
highly directed fashion by a mechanism involving the action
of speci¢c PKC isoforms, both in chroma⁄n cells and other
cell types.
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